[go: up one dir, main page]

WO2018080158A1 - Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait d'elaeagnus glabra en tant que principe actif - Google Patents

Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait d'elaeagnus glabra en tant que principe actif Download PDF

Info

Publication number
WO2018080158A1
WO2018080158A1 PCT/KR2017/011818 KR2017011818W WO2018080158A1 WO 2018080158 A1 WO2018080158 A1 WO 2018080158A1 KR 2017011818 W KR2017011818 W KR 2017011818W WO 2018080158 A1 WO2018080158 A1 WO 2018080158A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
cognitive impairment
composition
barley
narrow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/011818
Other languages
English (en)
Korean (ko)
Inventor
정수진
임혜선
김유진
김부여
손은진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2018080158A1 publication Critical patent/WO2018080158A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts

Definitions

  • the present invention is narrow leaf barley ( Elaeagnus) glabra ) relates to a composition for the prevention, improvement or treatment of cognitive impairment containing the extract as an active ingredient.
  • Cognition refers to all processes in which humans use their brains to think, speak, remember, judge, and execute. Therefore, 'cognitive function' includes attention, perception, memory, language ability, executive ability, etc., 'cognitive impairment' is the most prominent phenomenon of the aging of the brain, characterized by a decrease in learning, memory, and judgment It is a physiological phenomenon that is erased. In particular, these cognitive impairments may appear in various ways. Among them, dementia is markedly impaired in interpersonal relations, occupational functions, and daily life functions due to the decline in cognitive functions such as memory, language skills, visual perception and space-time composition ability, and executive functions. It is diagnosed as a complex disease that results. Geriatric dementia is mainly caused by Alzheimer's dementia.
  • Alzheimer's dementia is commonly referred to as Alzheimer's disease (AD), and it can be said to die slowly without any treatment efforts.
  • the disease was known in 1906 by Alois Alzheimer, a German neuropathologist.
  • Alois Alzheimer a German neuropathologist.
  • the elderly population of 72 million people was 720,000 in 1960, accounting for only 2.9%, but it is expected to become a full-fledged aging society, and after 2026, the population aged 65 or older will increase to 20% of the total population. .
  • the number of patients with senile dementia increases sharply in proportion to this. Experts predict that 10% of people over 65 years of age will suffer from senile dementia, and 40% to 50% of people over 85 years of age.
  • Cognitive dysfunction such as the loss of memory and learning ability caused by Alzheimer's disease (AD), a type of senile dementia, is caused by the aggregation and deposition of two insoluble proteins in the hippocampus and cortex. Protein aggregation is the accumulation of neurofibrillary tangles consisting of senile plaque composed of amyloid beta (A ⁇ ) and hyperphosphorylated tau protein in neurons.
  • AD Alzheimer's disease
  • a ⁇ amyloid beta
  • tau protein hyperphosphorylated tau protein
  • the narrow-leaved barley grows on the coast of the island, and its leaves are alternate, thick, glossy, and narrow. Both ends are narrow, 4 ⁇ 8cm long, petiole is short.
  • the outer surface of the brown virgin (star hair: star-shaped split hair) disappears and dense on the back. At the edges there are wavy teeth.
  • Calyx tube is long bell-shaped, end is divided into 4 branches, and stamen is 4.
  • Fruits are elliptical nucleus, 10-18mm long, silvery brown. Our lady is dense on the outside and ripens red in April- May. Breeding is by seed or folding. It is weak to cold, grows well in sunny places, and is strong in salt. Fruit is sweet and eats raw or dipped fruit liquor. It is distributed in Korea (Jeju).
  • the present invention is derived by the above requirements, relates to a composition for the prevention, improvement or treatment of cognitive impairment containing narrow leaf barley extract as an active ingredient, inhibiting amyloid beta aggregation of the narrow leaf barley extract,
  • the present invention was completed by confirming the antioxidant activity, neuronal cell protection and the inhibitory effect of brain cells.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of cognitive impairment containing narrow leaf barley berry extract as an active ingredient.
  • the present invention provides a health functional food composition for the prevention or improvement of cognitive impairment containing a narrow leaf barley berry extract as an active ingredient.
  • the present invention relates to a composition for the prevention, improvement or treatment of cognitive impairment containing a narrow barley barberry extract as an active ingredient, the narrow barley barberry extract inhibits amyloid beta aggregation, antioxidant activity, neuronal cell protection and brain cells Inflammatory effect and cognitive function because it has excellent effect in manual evasion experiment and Morris underwater maze experiment using Alzheimer's dementia animal model, and also in manual avoidance experiment and Y-maze experiment using short term memory disorder animal model. It can be used to prevent, ameliorate or treat a disorder.
  • (A) is a narrow leaf barley biloba branch extract
  • (B) to confirm the amyloid beta aggregation inhibitory effect of the narrow barley barberry leaf extract 100 ⁇ M of Morin compound was used as a positive control.
  • Figure 2 confirms the antioxidant activity of the narrow leaf barley biloba extract of the present invention
  • A is a result of confirming the ABTS radical scavenging activity of the narrow leaf barley biloba branch extract
  • B DPPH of the narrow leaf barley biloba branch extract
  • C is the result of confirming the ABTS radical scavenging activity of the narrow leaf barley berry leaf extract
  • D is the result of confirming the DPPH radical scavenging activity of the narrow leaf barley berry leaf extract.
  • Vitamin C vit. C
  • Vitamin C was used as a positive control.
  • Figure 3 confirms the neuronal protective effect (CCK) of the narrow leaf barley bran branch extract of the present invention
  • A to determine the cytotoxicity to the neuronal hippocampal cell line, treated with narrow leaf barley bran branch extract Survival rate is the result
  • B is a result of the treatment of H 2 O 2 to the nerve cells induced nerve cell damage, the treatment of narrow barley biloba branch extract to confirm the cytoprotective effect
  • C cell membrane damage The results of measuring LDH outflow and mitigating the effects of LDH outflow due to the treatment of Narrow-leaf Barley bran branch extract.
  • H 2 O 2 is statistically significant difference in cell survival rate or LDH release due to neuronal damage following treatment, p ⁇ 0.001.
  • **, *** is compared with the H 2 O 2 treatment group, by the treatment of the narrow barley bark branch extract showed that there is a statistically significant difference in the cell survival rate or LDH release of neurons, ** is p ⁇ 0.01 and *** means p ⁇ 0.001.
  • Figure 4 as a result of confirming the inhibitory effect on the brain cell inflammation according to the treatment of the narrow barley bark branch extract of the present invention
  • (A) is the result of confirming the toxicity of microglia cells
  • (B) is inflammation of BV-2 cells
  • (C) induces inflammation in BV-2 cells
  • ### means that the production of nitric oxide (NO) or PGE 2 was significantly increased by damage to neurons following LPS treatment, which means p ⁇ 0.001.
  • ** and *** indicate that NO (nitric oxide) or PGE 2 production was statistically significantly decreased by treatment of N. barberry extract compared to LPS treatment group, ** is p ⁇ 0.01 , *** means p ⁇ 0.001.
  • # I a statistically significant difference in the manual avoidance time of the control group treated with amyloid beta compared to the normal group (group not treated with amyloid beta), which means that p ⁇ 0.05, *, ** means amyloid beta and Negative leaf barley branch extract administration (50, 200mg / kg) group or positive control group (morin administration group) significantly improved passive avoidance time compared to the control group, * is p ⁇ 0.05, ** is p ⁇ 0.01.
  • Figure 7 is a result of confirming the effect of the narrow leaf barley bran branch extract according to the present invention in a passive avoidance experiment using a short-term memory disorder animal model.
  • # I a statistically significant difference in the passive avoidance time of the scopolamine-treated control group compared to the normal group (the group not treated with scopolamine), where p ⁇ 0.05, and ** is the scopolamine
  • the control group 50 mg / kg
  • narrow control barley bran branch extract Tacrine administration group
  • the present invention relates to a pharmaceutical composition for the prevention or treatment of cognitive impairment containing narrow leaf barley berry extract as an active ingredient.
  • the narrow leaf barley berry extract may be prepared by a method comprising the following steps, but is not limited thereto:
  • the extraction solvent in step 1) is preferably water, a lower alcohol of C 1 ⁇ C 4 or a mixture thereof, more preferably an ethanol extract, even more preferably 70% (v / v) ethanol ultrasonic extract It is not limited to this.
  • the narrow leaf barley may be extracted using any conventional method known in the art, such as filtration, hot water extraction, dipping extraction, reflux cooling extraction, and ultrasonic extraction.
  • the extraction solvent is preferably extracted by adding 1 to 20 times the volume of dried narrow leaf barley biloba, more preferably 3 to 10 times.
  • Extraction temperature is preferably 20 to 50 °C but is not limited thereto.
  • the extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, most preferably 1 hour is not limited thereto.
  • the reduced pressure concentration in step 3) is preferably a vacuum reduced pressure concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
  • the narrow-leaf barley berry extract may be an extract of an outpost, a flower, a leaf, a branch, a root or a seed, but is preferably a leaf or branch extract of a narrow-leaf barley.
  • the cognitive impairment is preferably any one selected from dementia, Alzheimer's, ischemic stroke, traumatic brain injury, forgetfulness, Parkinson's disease, pick disease, Creutzfeldt-Jakob disease, and mild cognitive impairment Do not.
  • mild cognitive impairment is defined as a pre-dementia clinical stage that does not cause a state in which memory and cognitive function is significantly lower than age and education level or disruption in life.
  • composition of the present invention may include a pharmaceutically acceptable carrier, excipient or diluent in addition to the active ingredient, and may be various oral or parenteral formulations.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • Solid preparations for oral administration include capsules, powders, granules, tablets, pills, and the like, which may comprise at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin.
  • lubricants such as magnesium stearate, talc and the like are also used.
  • Liquid preparations for oral administration include suspensions, emulsions, syrups, aerosols and the like, and may include various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • the base of the suppository As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycero gelatin and the like can be used.
  • parenteral administration it is desirable to select either external skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections, most preferably for external skin use.
  • composition according to the invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, the effective amount of the level of the disease, the severity, the drug activity of the patient , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.
  • the dosage of the composition of the present invention varies depending on the body weight, age, sex, health status, diet, time of administration, administration method, excretion rate and severity of the disease, the daily dosage of the narrow leaf barley extract 0.01-2,000 mg / kg, preferably 30-500 mg / kg, more preferably 50-300 mg / kg, based on the amount, can be administered 1-6 times per day.
  • the compositions of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.
  • the present invention relates to a health functional food composition for the prevention or improvement of cognitive impairment containing a narrow leaf barley berry extract as an active ingredient.
  • the composition is characterized by having antioxidant activity, the composition is preferably prepared in any one of the formulations selected from powders, granules, pills, tablets, capsules, candy, syrups and beverages, but is not limited thereto.
  • the narrow barley barley extract may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the blending amount of the active ingredient can be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment).
  • the composition of the present invention is added in an amount of up to 15 parts by weight, preferably up to 10 parts by weight based on the raw materials.
  • the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
  • the kind of food There is no particular limitation on the kind of food.
  • Examples of foods to which the extract or fractions thereof may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, drinks, tea , Drinks, alcoholic beverages and vitamin complexes, and includes all the health functional foods in the conventional sense.
  • composition of the present invention When the composition of the present invention is used as a health beverage, various flavors, natural carbohydrates, and the like may be contained as additional components, as in general beverages.
  • natural carbohydrates are sugars such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as textine and cyclotenstrin, xylitol, sorbitol and erythritol.
  • sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
  • the ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 g of the composition of the present invention.
  • the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And carbonation agents used in carbonated beverages.
  • the composition of the present invention may contain a pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not critical, but the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.
  • Narrow leaf barley leaves and branches were used from the Medicinal Plant Material Bank of Gachon University. 5 liters of 70% (v / v) ethanol was added to 500.0 g of each dried sample of the barley bark leaves and branches and ultrasonically extracted three times for 1 hour using an ultrasonic extractor. The ultrasonic extract was filtered using Advantec No. 2 (110 mm) filter paper to remove insoluble matters, and then concentrated under reduced pressure at 40 ° C. with a condenser equipped with a cooling condenser. To completely remove the solvent of the concentrated extract under reduced pressure, 500 ml of purified water was added and suspended, and then concentrated by using a lyophilizer.
  • Amyloid beta aggregation inhibitory activity was measured by fluorescence assay.
  • Amyloid beta (A ⁇ 1-42 ) peptide was stored at minus 80 °C, the final concentration used in the measurement was used to 100 ⁇ m / ml.
  • Thioflavin T used as a fluorescent substance, was dissolved in assay buffer (50 mM Tris / 150 mM NaCl (pH 7.2), 20 mM HEPES / 150 mM NaCl (pH 7.2), 10 mM phosphate / 150 mM NaCl (pH 8.0)). It was prepared and used at a concentration of 2 mM. Samples were dissolved in assay buffer and used at a final concentration of 100 ⁇ g / ml.
  • Antioxidant efficacy measurement using ABTS (2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid)) radical was carried out by modifying the ABTS + cation decolorization assay method to 96 well plates. 7 mM ABTS and 2.45 mM potassium persulfate were mixed at the final concentration and left for 24 hours in the dark at room temperature to form ABTS +. And diluted with PBS to have an absorbance value of 0.7 at 743 nm. After mixing ABTS + solution and the sample in a 96 well plate and reacting at room temperature for 30 minutes, the absorbance was measured at 743 nm using an Epoch Microplate Spectophotometer. The radical scavenging activity of each sample was expressed as a percentage of the radical scavenging ability with respect to the control group using PBS as a control group. Vitamin C (vit. C) was used as a positive control for activity comparison.
  • Antioxidant potency measurements using DPPH (1-1-diphenyl-2-picrylhydrazyl) radicals were performed using 96 well plates. 0.15 mM DPPH solution and the sample were mixed in a 96 well plate and reacted at room temperature for 30 minutes, and then the absorbance was measured at 517 nm.
  • the antioxidant activity of each treatment extract was expressed as a percentage of radical scavenging ability with respect to the control group using the solvent DMSO as a control. Vitamin C (vit. C) was used as a positive control for activity comparison.
  • Cell Counting Kit-8 (CCK-8) was used according to the manufacturer's instructions. Samples were treated by concentration in HT22 cell lines (5 ⁇ 10 3 cells / well) dispensed in 96-well plates and incubated for 24 hours. After incubating for 4 hours with 10 ⁇ l of CCK-8 solution, absorbance was measured at 450 nm and relative cell viability (% of control) was calculated by comparison with the control group.
  • H 2 O 2 hydrogen peroxide
  • HT22 cells were treated with 250 ⁇ M of hydrogen peroxide (H 2 O 2 ) for 6 hours. After the culture supernatant was collected, the mixture was mixed with the LDH substrate solution in the same amount and reacted at room temperature for 30 minutes. Then, 1N HCl was added to stop the reaction, and the absorbance was measured at 490 nm (experimental LDH release).
  • H 2 O 2 hydrogen peroxide
  • % Cell survival rate ⁇ [experimental LDH release (OD 490 )] / [Maximum LDH release (OD 490 )] ⁇ ⁇ 100
  • Samples were treated by concentration in BV-2 cell lines (1 ⁇ 10 4 cells / well) dispensed in 96-well plates and incubated for 24 hours. After incubating for 4 hours with 10 ⁇ l of CCK-8 solution, absorbance was measured at 450 nm and relative cell viability (% of control) was calculated by comparison with the control group.
  • LPS lipopolysaccharide, 1 ⁇ g / ml
  • ELISA enzyme-linked immunosorbent assay
  • 12-week-old male mouse (C57BL / 6N, coretech) of 23-28 g has temperature 23 ⁇ 3 degrees Celsius, relative humidity 55 ⁇ 15%, ventilation times 10-20 times / hr, lighting time 12 hours (8 am lighting-afternoon 8 o'clock) and roughness of 150-300 Lux were kept in the animal room. All experimental procedures were conducted in accordance with the NIH Guidelines for the Management and Use of Laboratory Animals. Animal handling was conducted in accordance with the National Animal Welfare Law of Korea.
  • Passive avoidance experiments were performed at the same time for three consecutive days at 24 hour intervals.
  • the animals On the 8th day of the administration of the test substance, the animals were kept in the shaded area for 2 minutes, and then put back in the illuminated area and immediately taken out to the shaded area for adaptive training. Twenty-four hours after the 9th day of the test substance administration, two training sessions were performed every two minutes.
  • animals were placed in the chamber of a passive avoidance test instrument for 60 seconds to adjust the instrument. At this time, the guillotine door was opened without lighting so that the animals could freely enter and exit.
  • 7-week-old male mouse (ICR, central laboratory animal) of 23-28 g has temperature 23 ⁇ 3 °C, relative humidity 55 ⁇ 15%, ventilation times 10-20 times / hr, lighting time 12 hours (8 am lighting-8 pm Litter) and was maintained in the animal room maintained at roughness 150 ⁇ 300 Lux. All experimental procedures were conducted in accordance with the NIH Guidelines for the Management and Use of Laboratory Animals. Animal handling was conducted in accordance with the National Animal Welfare Law of Korea.
  • Passive avoidance experiments were performed at the same time for three consecutive days at 24 hour intervals.
  • the animals On the 10th day of administration of the test substance, the animals were allowed to stay in the shaded area for 2 minutes, and then placed in the illuminated area again and immediately taken out to the shaded area for adaptive training. Twenty-four hours after the 11th day of test substance administration, two training sessions were performed every two minutes.
  • animals were placed in a passive avoidance test instrument chamber for 60 seconds to adjust the instrument. At this time, the guillotine door was opened without lighting so that the animals could freely enter and exit.
  • Y-maze experiments were conducted on day 14 of test substance administration.
  • Y-maze is made of black acrylic in the shape of a four-sided maze that is made of four, each of the three A, B, C, then carefully placed the mouse on one branch and let it move freely for 8 minutes
  • the branches containing the mice were recorded in order. It continued when the tail had been completely entered, even when it had entered the branch that had once entered.
  • Change behavior was calculated by the following equation.
  • narrow barley bark branches and leaf extracts inhibited amyloid beta aggregation in a concentration-dependent manner, and inhibited amyloid beta aggregation when treated with narrow barley bark branches extract of 50 ⁇ g / ml or more. It was confirmed that is more than 60%.
  • Example 2 ABTS radical scavenging activity and DPPH radical scavenging activity were confirmed in order to confirm the antioxidant activity of the narrow barley barberry and leaf extract. As shown in FIG. At 25 ⁇ g / ml or more, 100% ABTS radical scavenging activity and DPPH radical scavenging activity were observed, and when the concentration of the narrow leaf barberry leaf extract was 100 ⁇ g / ml, it showed almost 100% ABTS radical scavenging activity.
  • Example 3 it was confirmed that the narrow barley bark branch extract has little cytotoxicity against normal neurons (FIG. 3 (A)), and due to H 2 O 2 damage to neurons, cell survival rate is reduced. , By treating the narrow leaf barley bran extract to damage the neurons caused by H 2 O 2 , it was confirmed that there is an effect of suppressing the decrease in cell viability (FIG. 3 (B)), by H 2 O 2 Neuronal cell membranes are damaged and LDH release is increased, but by treating the narrow leaf barley bran extract, the effect of mitigating the increase in LDH release was confirmed (Fig. 3 (C)).
  • Example 4 confirmed the inhibitory effect on brain cell inflammation, and as a result, as shown in Figure 4, the narrow barley bark branch extract of the present invention is almost non-toxic to the brain cells, the cell survival rate is maintained at 100% level.
  • the amount of nitric oxide (NO) is increased, whereas the amount of nitric oxide (NO) is significantly reduced when the barley bark branch extract of the present invention is treated.
  • the amount of PGE 2 was increased when inflammation was induced, whereas the treatment group of the Narrow bark branch extract was found to decrease PGE 2 in a concentration-dependent manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition visant à prévenir, améliorer ou traiter un trouble cognitif, la composition contenant un extrait d'Elaeagnus glabra en tant que principe actif, et plus spécifiquement, l'extrait d'Elaeagnus glabra selon la présente invention présente une activité antioxydante, une activité d'inhibition de l'agrégation du peptide bêta-amyloïde, un effet de protection des cellules nerveuses et un effet d'inhibition de l'inflammation des cellules cérébrales, et peut ainsi être utilisé utilement en tant que composition pour prévenir, améliorer ou traiter un trouble cognitif.
PCT/KR2017/011818 2016-10-25 2017-10-25 Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait d'elaeagnus glabra en tant que principe actif Ceased WO2018080158A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0139001 2016-10-25
KR1020160139001A KR101807607B1 (ko) 2016-10-25 2016-10-25 좁은잎보리장나무 추출물을 유효성분으로 함유하는 인지기능 장애의 예방, 개선 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2018080158A1 true WO2018080158A1 (fr) 2018-05-03

Family

ID=60943529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/011818 Ceased WO2018080158A1 (fr) 2016-10-25 2017-10-25 Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait d'elaeagnus glabra en tant que principe actif

Country Status (2)

Country Link
KR (1) KR101807607B1 (fr)
WO (1) WO2018080158A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033946A1 (fr) * 2022-08-10 2024-02-15 Dr Dozo Laboratories Compositions et utilisation dans des méthodes de traitement d'un déficit cognitif
CN118995502A (zh) * 2024-08-20 2024-11-22 中国农业大学 一种改善学习记忆的长双歧杆菌与大麦叶的组合物及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102782232B1 (ko) * 2020-11-30 2025-03-18 주식회사 오로라에스 한삼덩굴 잎 추출물 및 생강 추출물의 혼합물을 유효성분으로 함유하는 인지기능 장애의 예방, 개선 또는 치료용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003095884A (ja) * 2001-09-27 2003-04-03 Kankyo Hozen Kenkyusho:Kk ツルグミを用いた育毛剤原料
KR100780893B1 (ko) * 2006-06-21 2007-11-29 대구한의대학교산학협력단 뜰보리수 과실 추출물을 유효성분으로 함유하는 항산화,항염 및 미백용 조성물
JP2011195531A (ja) * 2010-03-23 2011-10-06 Shiseido Co Ltd タンパク質糖化抑制剤
KR20120021516A (ko) * 2010-08-05 2012-03-09 우석대학교 산학협력단 기억력 개선, 인지능력 개선, 치매 예방, 지연 또는 치료 효과를 나타내는 조록나무 추출물, 이를 유효성분으로 하는 약제학적 조성물, 이를 유효성분으로 포함하는 기능성 건강보조식품 및 조록나무 추출물의 제조방법
CN105148022A (zh) * 2015-09-30 2015-12-16 郑梅 治疗老年痴呆的方剂及制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003095884A (ja) * 2001-09-27 2003-04-03 Kankyo Hozen Kenkyusho:Kk ツルグミを用いた育毛剤原料
KR100780893B1 (ko) * 2006-06-21 2007-11-29 대구한의대학교산학협력단 뜰보리수 과실 추출물을 유효성분으로 함유하는 항산화,항염 및 미백용 조성물
JP2011195531A (ja) * 2010-03-23 2011-10-06 Shiseido Co Ltd タンパク質糖化抑制剤
KR20120021516A (ko) * 2010-08-05 2012-03-09 우석대학교 산학협력단 기억력 개선, 인지능력 개선, 치매 예방, 지연 또는 치료 효과를 나타내는 조록나무 추출물, 이를 유효성분으로 하는 약제학적 조성물, 이를 유효성분으로 포함하는 기능성 건강보조식품 및 조록나무 추출물의 제조방법
CN105148022A (zh) * 2015-09-30 2015-12-16 郑梅 治疗老年痴呆的方剂及制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033946A1 (fr) * 2022-08-10 2024-02-15 Dr Dozo Laboratories Compositions et utilisation dans des méthodes de traitement d'un déficit cognitif
CN118995502A (zh) * 2024-08-20 2024-11-22 中国农业大学 一种改善学习记忆的长双歧杆菌与大麦叶的组合物及应用

Also Published As

Publication number Publication date
KR101807607B1 (ko) 2017-12-11

Similar Documents

Publication Publication Date Title
WO2018080156A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait de potentilla fragarioides en tant que principe actif
WO2010058926A2 (fr) Composition pharmaceutique contenant un extrait de gingembre ou du shogaol
CN108472325B (zh) 包含蜂斗菜叶提取物的用于改善记忆力的组合物
WO2010036052A2 (fr) Composition contenant 4-o-méthylhonokiol pour traiter ou prévenir des maladies liées aux amyloïdes
WO2016032249A1 (fr) Composition pharmaceutique contenant un extrait de vaccinium bracteatum thunb. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2024096280A1 (fr) Composition pour la prévention, l'atténuation ou le traitement de la maladie d'alzheimer contenant comme principe actif un extrait de tige de vitis vinifera ou un composé isolé de celui-ci
WO2018080158A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait d'elaeagnus glabra en tant que principe actif
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
WO2018080157A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'un déficit cognitif, contenant un extrait de ficus erecta en tant que principe actif
WO2012108749A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de graines de pharbitis
WO2018026103A1 (fr) Composition pour la régénération cellulaire comprenant un extrait d'axe floral de ginseng
WO2020138834A1 (fr) Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée
WO2024058552A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies cérébrales dégénératives, comprenant des cannabinoïdes en tant que principe actif, et ses utilisations
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2023054918A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du dysfonctionnement cognitif comprenant, comme principes actifs, des cellules souches à néprilysine surexprimée, leurs solutions de culture et les exosomes isolés à partir de celles-ci
WO2012108747A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait de la racine d'helena
KR101414988B1 (ko) 오배자 추출물을 유효성분으로 포함하는 인지력 개선 및 치매 예방 또는 치료용 조성물
WO2021085741A1 (fr) Composition d'amélioration ou de traitement de la maladie d'alzheimer comprenant comme principe actif du tetragonia tetragonioides
WO2012108744A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de la fleur inula
WO2012108745A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de gleditsiae semen
WO2012108743A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait des graines de pharbitis blanc
KR100839131B1 (ko) 오보바톨을 함유하는 아밀로이드 관련 질환의 치료 또는예방용 조성물
WO2012108746A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait de racine de rubia cordifolia
WO2018155956A1 (fr) Composition pharmaceutique, contenant un extrait de bulbe de lis, dans le traitement prophylactique ou thérapeutique d'un trouble cognitif
WO2024136061A1 (fr) Composition pour prévenir ou traiter un dysfonctionnement cognitif ou des maladies associées à un trouble de la mémoire comprenant un extrait de ligustrum foliosum nakai

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17865205

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17865205

Country of ref document: EP

Kind code of ref document: A1